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Abstract
Background: The objective of this study is to investigate the role and experience of early stage non-small cell lung
cancer (NSCLC) patient in decision making process concerning treatment selection in the current clinical practice.
Methods: Stage I-II NSCLC patients (surgery 55 patients, SBRT 29 patients, median age 68) were included in this
prospective study and completed a questionnaire that explored: (1) perceived patient knowledge of the advantages and
disadvantages of the treatment options, (2) experience with current clinical decision making, and (3) the information that
the patient reported to have received from their treating physician. This was assessed by multiple-choice, 1–5 Likert Scale,
and open questions. The Decisional Conflict Scale was used to assess the decisional conflict. Health related quality of life
(HRQoL) was measured with SF-36 questionnaire.
Results: In 19% of patients, there was self-reported perceived lack of knowledge about the advantages and
disadvantages of the treatment options. Seventy-four percent of patients felt that they were sufficiently involved in
decision-making by their physician, and 81% found it important to be involved in decision making. Forty percent
experienced decisional conflict, and one-in-five patients to such an extent that it made them feel unsure about the
decision. Subscores with regard to feeling uninformed and on uncertainty, contributed the most to decisional conflict,
as 36% felt uninformed and 17% of patients were not satisfied with their decision. HRQoL was not influenced by
patient experience with decision-making or patient preferences for shared decision making.
Conclusions: Dutch early-stage NSCLC patients find it important to be involved in treatment decision making. Yet a
substantial proportion experiences decisional conflict and feels uninformed. Better patient information and/or
involvement in treatment-decision-making is needed in order to improve patient knowledge and hopefully reduce
decisional conflict.
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Background
Surgical resection is considered the preferred treatment
for patients with early-stage non-small cell lung cancer
(NSCLC). A less invasive option for patients with comor-
bidities is stereotactic body radiotherapy (SBRT) [1, 2].
Several studies have demonstrated that SBRT may be as
effective as surgery in potentially operable patients, how-
ever, randomized trials with larger patient populations and
longer follow-up are still lacking [3–5]. In this setting it is
important to provide adequate information to allow pa-
tients to take an active role in treatment decision.
Shared decision making (SDM) is a process in which
physician and patient work together in making a health de-
cision after discussing the options, the benefits and harms,
and considering the patients’ values, preferences, and cir-
cumstances [6, 7]. SDM is seen as the middle ground be-
tween informed choice, where the patient makes the
decision based on information received from the physician,
and traditional paternalistic decision making, where the
physician makes the decision based on best available
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evidence [8, 9]. Patients who are active participants in the
process of their care, for example asking questions, express-
ing their opinions and preferences, have better health out-
comes, more knowledge regarding the disease and they are
less anxious than patients who do not participate in the de-
cision making [7, 10–12]. SDM supports patient to under-
stand the disease and weigh advantages and disadvantages
of treatment options in their own context, which will result
in an informed treatment decision making with patients’
needs and values incorporated. Although SDM has gained
increased awareness among the healthcare community, it
has not been widely incorporated into routine clinical prac-
tice in lung cancer care. This can be explained by the fact
that there is lack of familiarity with SDM [13, 14], and also
because the care of lung cancer patient can be complex due
to multiple treatment types over an extended period of time
and often includes a guideline-drive treatment [15]. Fur-
thermore, there are a number of factors that complicate the
implementation of SDM in current clinical practice such as
guideline based treatments, patient knowledge, time con-
strains and care settings [16, 17].
This study assesses among Dutch early-stage NSCLC
patients: (1) perceived patient knowledge of the advan-
tages and disadvantages of treatment options, (2) experi-
ence with current clinical decision-making, and (3)
perceived understanding of information regarding their
disease and the treatment.
Methods
Patient population
Between December 2012 and December 2014, 155 con-
secutive patients with stage I or II NSCLC were recruited
for this prospective observational study. These patients
were subsequently treated surgically or with SBRT at Eras-
mus University Medical Center, Erasmus MC-Cancer In-
stitute, or Amphia Hospital Breda. Consecutive patients
were contacted by telephone to explain the purpose of the
study and obtain their consent to receive a questionnaire.
Only patients who agreed to participate and provided
written informed consent were eligible for the inclusion in
this study (n = 84). The overall response rate was 54%. No
significant differences were found between responders
and non-responders in terms of baseline characteristics.
This study was approved by the institutional review board
of Erasmus University Medical Center (MEC 2012-462).
Clinical staging of patients treated surgically (n = 55) or
with SBRT (n = 29) was done with CT-scan, 18FDG-PET
imaging and/or using (minimally invasive) endoscopic tech-
niques when appropriate. Clinical and pathological staging
was based on American-Joint-Committee-in-Cancer 7th-
edition staging manual [18]. Chronic obstructive pulmonary
disease (COPD) was defined according to the GOLD
criteria [19]. Comorbidity-scores were recorded using the
Charlson-Comorbidity-Index (CCI) [20]. Treatment
planning of patients who received SBRT have been de-
scribed previously [21]. All patients were discussed in a
multidisciplinary team meeting before being accepted for
treatment.
Data collection
Baseline characteristics of patients were collected by
reviewing the patients’ medical records and hospital infor-
mation system. After the treatment decision was made
but before the actual start of the treatment, patients com-
pleted a questionnaire. The aim of this questionnaire is to
investigate: (1) perceived patient knowledge of the advan-
tages and disadvantages of treatment options, (2) experi-
ence with current clinical decision-making (this includes
the preferences, patient experience and involvement in
treatment decision-making using Decisional Conflict Scale
(DCS) and Control Preferences Scale (CPS), and (3) per-
ceived understanding of information regarding their dis-
ease and the treatment. These components are measured
at baseline using multiple-choice questions, a 1–5 Likert
Scale, and open questions. Health-related-quality-of-life
(HRQoL) was measured before the treatment, 6 months
and 12 months after the treatment using the Short-Form
36-Item Health Survey (SF-36). For details regarding the
questionnaire see Additional file 1.
Control preference scale
The patients’ preferred decisional role was assessed using
a modified version of the CPS. The CPS is an instrument
that assesses preferences regarding patient participation in
health care decisions. Patients were asked to select one of
the five statements on roles in treatment decision-making;
(A) the physician makes the decision about the treatment
alone, (B) the physician makes the decision after consider-
ing the patient’s opinion, (C) the patient makes the deci-
sion together with the clinician, (D) the patient makes the
decision after considering the doctor’s opinion, and (E)
the patient makes the decision about the treatment alone
[22–24]. This scale has been widely used in previous stud-
ies [25, 26]. To investigate the potential association be-
tween education level and CPS patients were asked to
indicate their educational attainment.
Decisional conflict scale
The DCS was used to assess the level of ‘decisional
conflict’ that patients experience while making health
care decisions. This scale has been extensively vali-
dated and has been widely used. The DCS measures
decision uncertainty that leads to decision delay, and
quantifies modifiable factors which contribute to un-
certainty. It contains 16 items, each using a five-point
Likert response format (i.e. completely agree, agree,
neither agree nor disagree, disagree, completely dis-
agree). These items are combined to form total score
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and five subscales (i.e. uncertainty, informed, values
clarity, support, and effective decision subscore).
Scores lower than 25 are associated with implement-
ing decisions and scores exceeding 37.5 are associated
with delay or feeling unsure about implementation
[27, 28]. In case of missing values (<6%) we used a
multiple imputation technique to impute missing
values in order to avoid them being depicted as ‘un-
known’ in incomplete observations. We have used 5-
fold multiple imputation using SPSS for Windows
version 21 [29]. In the surgery group 32 and 19 pa-
tients were alive at 6 and 12 months without tumor
progression, respectively. In the SBRT group this was
9 and 4 patients at 6 and 12 months, respectively.
Due to the low response rates at 6 and 12 months
we could not explore decisional conflict over time.
Health related quality of life assessment
HRQoL was measured with the SF-36. The SF-36 is the
most extensively used and evaluated health outcomes
measure and has shown to be valid and reliable in mul-
tiple populations. The SF-36 assess eight self-reported
aspects of HRQoL (i.e. physical functioning, role phys-
ical functioning, role emotional functioning, mental
health, vitality, social functioning, bodily pain, and gen-
eral health). It also yields physical (PCS) and mental
(MCS) health summary measures. Scale scores are ob-
tained by summing the items together within a domain,
dividing this outcome by the range of scores and then
transforming the scores to a scale from 0 to 100 [30].
The mean score of the PCS and MCS is 50 with a
standard deviation of 10 and wherein a higher score
means a better health status. Furthermore, a higher
score on the SF-36 subdomains represents a better
functioning; a high score on the bodily pain scale indi-
cates the absence of pain. The scale has good reliability,
with Cronbach α ranging from 0.65 to 0.96 for all sub-
scales [31]. We used the Dutch adaptation of the SF-36
health status scale [32]. Patients were asked to
complete the SF-36 form after treatment decision was
made but before the treatment (baseline), at 6 and
12 months to all surviving patients. In case of missing
values we applied simple imputation [33, 34]. HRQoL
was assessed in 84 patients at baseline (surgery = 55,
SBRT = 29). Due to the low response rates at 6 and
12 months (surgery group 32 and 19 patients were alive
at 6 and 12 months and this was in the SBRT group 9
and 4 patients, respectively) the effect of time could not
be analyzed.
Local control and the presence of metastases were de-
fined according to the guidelines of ACCP and STS [35].
Twelve patients were diagnosed with tumor recurrence
after the treatment, four of these patients had both loco-
regional and distant recurrence.
Statistical analysis
Continuous data are reported as mean ± SD or median
with range, and categorical data are reported as propor-
tions. Normally distributed continuous variables were
compared by using Student t tests, and not normally dis-
tributed (Kolmogorov-Smirnov) data were compared by
using the Mann-Whitney-U-test. Discrete variables were
compared by using the Chi-Square test or the Fisher
Exact test where appropriate. Aim 1 and 3 of this manu-
script were analyzed using simple statistics by counting
the ‘yes’ and ‘no’ answers. Components measured with
1–5 Likert-scale were not categorized.
A general linear model (GLM) with the bootstrap
method was used to assess the association between
HRQoL measured at baseline and 1) patient experience
with involvement in treatment selection, 2) patient pref-
erences for SDM, and 3) patients’ preferred decisional
role in treatment decision-making (assessed with CPS).
The purpose behind the use of bootstrapping is to ac-
count for skewed distribution of residuals of SF-36 vari-
ables [36, 37] and to obtain valid and reliable p-values.
All statistical tests were two-tailed and a p-value of
<0.05 was regarded as statistical significant. The statis-
tical software package SPSS for Windows version 21
(SPSS Inc., Chicago, IL) was used for data analysis.
GraphPad Prism5.00 for Windows (GraphPad software,
San Diego, CA) was used to obtain graphs of QoL.
Results
The baseline characteristics of all 84 patients are listed
in Table 1. In 55 patients surgical treatment was chosen
(median age = 65), in 29 patients SBRT (median age =
73). In this cohort of patients the education level was in
accordance with the education level of the general Dutch
population [38].
Perceived patient knowledge regarding the treatment
Self- reported lack of knowledge about the advantages and
disadvantages of the treatment options was present in 18%
of patients in the surgery group and in 22% of patients in
the SBRT group. Self-reported lack of knowledge about
the treatment risks was present in 6% of patients in the
surgery group and in 21% of patients in the SBRT group.
Experience with current clinical decision-making
Patient preferences for SDM
The majority (85%) of patients agreed that ideally
decision-making should be done together with the
physician. Twelve percent of patients wanted to leave
the decision about the appropriate treatment to their
treating physician and 3% indicated that the decision
should be done mainly by patients. No association
was found between the education level and the con-
trol preference scale.
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Table 1 Patient characteristics
Characteristics Total (n = 84) Surgery (n = 55) Radiotherapy (n = 29) P-value
Sex 0.406
-Male (%) 44 (52) 27 (49) 17 (59)
-Female (%) 40 (48) 28 (51) 12 (41)
Age, median (range) 68 (50–87) 65 (50–81) 73 (52–87) 0.001
Education level (%): 0.875
-Primary education 12 (14) 8 (15) 4 (14)
-Secondary education 21 (55) 29 (53) 17 (59)
-Higher education 46 (27) 15 (27) 8 (27)
-Other 3 (4) 3 (5) –
Smoking habits
-Nonsmoker (%) 3 (4) 2 (4) 1 (3) 0.588
-Current or former smoker (%) 60 (71) 38 (69) 22 (76)
-Unknown, n (%) 21 (25) 15 (27) 6 (21)
FEV1% mean ± SD
a 80 (24) 87 (20) 67 (26) 0.001
-Unknown, n (%) 3 (4) 2 (4) 1 (3)
DLCO (%) mean ± SDb 76 (24) 83 (22) 61 (22) <0.001
COPD (%)c 0.001
-No COPD 38 (45) 31 (56) 7 (24)
-GOLD I 17 (20) 10 (18) 7 (24)
-GOLD II 19 (23) 13 (24) 6 (21)
-GOLD III 8 (10) 1 (2) 7 (24)
-GOLD IV 2 (2) – 2 (7)
Charlson comorbidity index (%) 0.026
- ≤ 1 47 (56) 33 (60) 14 (48)
-2–3 26 (31) 17 (31) 9 (32)
-4 6 (7) 3 (5) 3 (10)
- ≥ 5 5 (6) 2 (4) 3 (10)
Clinical stage (%) 0.001
-IA 47 (56) 22 (40) 25 (86)
-IB 14 (17) 12 (22) 2 (7)
-IIA 17 (20) 15 (27) 2 (7)
-IIB 6 (7) 6 (11)
Pathological stage (%)
-IA 17 (31) 17 (31) –
-IB 18 (33) 18 (33) –
-IIA 9 (16) 9 (16) –
-IIB 7 (13) 7 (13) –
-IIIA/B 4 (7) 4 (7) –
Histology (%) 0.262
-Squamous cell carcinoma 18 (21) 14 (26) 4 (14)
-Adenocarcinoma 21 (25) 15 (27) 6 (21)
-Large cell carcinoma 8 (10) 6 (11) 2 (7)
-NSCLC 37 (44) 20 (36) 17 (58)
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Experience in treatment decision-making
On average, patients in this cohort discussed their treat-
ment with three physicians. The majority of patients in
the surgery and SBRT group involved a family member
in making the choice for a treatment, 75 and 68%, re-
spectively. Most of patients thought that they had
enough time to make an informed decision (80% in the
surgery group and 79% in the SBRT group). Patients in-
dicated that several subjects were discussed during the
conversation with their treating physician. Two percent
of patients in the surgery group had the feeling that not
every aspect of the treatment was discussed during the
conversation with their treating physician. This was 11%
in the SBRT group.
In the surgery group, 40% of patients experienced de-
cisional conflict (score > 25), and 22% to such an extent
that they felt unsure about their decision (score > 37.5).
Thirty-two percent felt uncertain about the best choice,
and 39% felt uninformed. Twenty-nine percent felt un-
clear about personal values for benefits and side effects
of the treatment. Twenty-one percent felt unsupported
in decision-making, and 21% of patients were not satis-
fied with their decision.
In the SBRT group, 48% of patients experienced deci-
sional conflict, and 7% to such an extent that they felt
unsure about their decision. Thirty-five percent felt un-
certain about the best choice, and 29% felt uninformed.
Thirty-two percent felt unclear about personal values
for benefits and side effects of the treatment. Fourteen
percent felt unsupported in decision-making, and 7% of
patients were not satisfied with their decision. Sub-
scores on feeling uninformed and on uncertainty
contributed the most to decisional conflict. Scores ex-
ceeding 37.5 are described here, details of the total
score and five subscales for the two treatment groups
are illustrated in Fig. 1.
Involvement in treatment decision-making
Seventy-four percent of patients felt that they were suffi-
ciently involved in decision-making by their physician,
73% felt that they had a choice between different treat-
ment options, 81% found it important to be involved in
decision-making, 6% reported that alternative treatment
options and complementary treatments were not dis-
cussed during the conversation about their treatment.
Patients mentioned immunotherapy, diet and vitamin
supplements as an example. Involvement in treatment
decision-making for the two treatment groups can be
found in Table 2.
Perceived understanding of information regarding the
disease and the treatment
Patients were asked to report which topics were dis-
cussed during the conversation about their treatment.
Figure 2 illustrates that the minority of patients who
undergone surgery or radiation therapy received infor-
mation about the survival, 24 and 18%, respectively.
Health related quality of life assessment
At baseline, patients in the surgery group scored higher
on physical component summary (mean 42.4 ± 12.3)
than patients in the SBRT group (mean 34.4 ± 10.1),
Fig. 3. No major differences could be found between the
HRQoL in the surgery and SBRT group for the other
measured SF-36 scales, except for physical functioning
and general health (Fig. 4). Recurrence rates and death
rates are illustrated in Table 3.
SDM and HRQoL at baseline
No significant association could be found between
HRQoL and patient experience with involvement in
treatment selection (PCS p-value = 0.398, MCS p-value
= 0.341), patient preferences for SDM (PCS p-values =
0.439, MCS p-value = 0.580), and final decision in lung
cancer treatment selection (PCS p-value = 0.402, MCS
p-value = 0.662).
Discussion
This study illustrate that in the current clinical prac-
tice lung cancer patients experience decisional conflict
and suboptimal information provision regarding the
treatment and survival which highlights the need of
improvement of information conveyance, and involve-
ment of patients with early-stage NSCLC in treatment
decision-making.
Perceived patient knowledge regarding the treatment
and communication with the patient
Up to one-fifth of patients reported lack of knowledge
about the advantages and disadvantages of the
Table 1 Patient characteristics (Continued)
Characteristics Total (n = 84) Surgery (n = 55) Radiotherapy (n = 29) P-value
Clinical tumor diameter (mm), median (range) 25 (7–130) 29 (7–130) 22 (9–41) <0.001
-Unknown, n (%) 11 (5) –
Pathological tumor diameter (mm), median (range) 28 (1–90) 28 (1–90) –
aFEV1%: Forced expiratory volume in 1 s expressed as a percent of predicted
bDiffusion capacity of the lung for carbon monoxide
cCOPD: chronic obstructive pulmonary disease
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treatment options and one-tenth of patients reported
lack of knowledge about the treatment risks. These re-
sults illustrate that providing information needs to im-
prove, particularly in an early stage of diagnosis and
treatment because lung cancer patients are emotionally
unstable and could be overloaded with information
about their disease [39]. Numerous studies explored
different strategies to improve and adopt SDM in clin-
ical practice [40]. One of the main topics of improving
cancer communication is ‘health literacy’ which in-
volves the ability of the patient to read, understand, and
use health information to make an appropriate deci-
sion. In order to achieve an effective communication it
is essential to describe health state in language that is
accessible to the patient and discuss the benefits and
risks of treatment options in a balanced way [41, 42]. In
the field of breast cancer it is illustrated that by decid-
ing on a cancer treatment without fully understanding
the associated risks and benefits could lead to overuse
or underuse of cancer treatments [43, 44].
Additionally, the majority of patients felt sufficiently
involved in treatment decision-making and indicated
that they had enough time to make an informed deci-
sion. It was interesting to see that the minority of pa-
tients reported to have received information on survival.
It is crucial to discuss survival and prognosis with the
patient in a way that the patient will understand this
Fig. 1 Decisional conflict in patients treated surgically or with stereotactic body radiotherapy (SBRT). Scores <25 (green smiley) are associated
with implementing decisions and scores <37.5 (red smiley) are associated with delay or feeling unsure about implementation. Orange smiley
represent scores between 25 and 37.5
Table 2 Involvement in treatment decision making for the two
treatment groups
Involvement in decision making Surgery (%) Radiotherapy (%)
- Felt sufficiently involved 78 68
- Found important to be involved 78 89
- Having a choice 71 79
- Not having a choice 18 7 Fig. 2 Information that the patient received during the consultation
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information because previous studies have shown that
the cancer patients overestimate their life expectancy
and probabilities of cure when compared to their physi-
cians’ perspective [45–47]. This will lead to unrealistic
high expectations about the medical treatment which is
a common phenomenon in oncology patients [48, 49].
Experience with current clinical decision-making
The majority of patients had a strong desire to partici-
pate in treatment decision-making and preferred the de-
cision to be the outcome of a SDM-process. This is in
line with the previous studies showing that more pa-
tients preferred to participate rather than delegate deci-
sions [50]. One of the challenges of SDM is knowing
how much involvement a patient wants and needs. It is
even more difficult when patients vary in the amount of
control that they prefer to have over the treatment
decision-making at the time of diagnosis [26]. Using
tools such as decision aids prior to the consultation or
during the visit will improve the communication be-
tween the patient and physician and there will be more
time for the patient to absorb health care information
and ask questions during the consultation [51, 52].
Forty percent of patients experienced decisional con-
flict, and one in five patients to such an extent that it
made them feel unsure about the decision. Decisional
conflict was most evident in the uncertainty and in-
formed subscale, suggesting that improvement of patient
uncertainty and better informing the patient before the
treatment will improve the quality of decision-making
[27]. The same rates has been reported by patients
treated for other type of cancer [53, 54]. Various factors
can play a role in high levels of decisional conflict in
cancer patients. First, most cancer patients want as
much information as possible, however, they could be
overloaded with information when it is offered ‘all at
once’ or when the information is not provided to the pa-
tients’ family [55]. As we have illustrated in this study,
an inadequate level of perceived information contributes
the most to decisional conflict. Second, periodic assess-
ment of cancer patient’s information requirements is
also crucial, considering the complexity of cancer care.
Finally, in our previous study we have illustrated that pa-
tients who receive SBRT differ significantly from the sur-
gical patients [56]. It is important to appreciate these
differences and realize that SBRT patients do not always
have a choice between treatment options.
Fig. 3 Scatterplot of physical component summary (PCS) and mental component summary (MCS) at baseline in the surgery and stereotactic
body radiotherapy (SBRT) group
Fig. 4 Eight self-reported aspects of HRQoL measured at baseline. The
scores are expressed as the mean score with a standard deviation
stratified by treatment group. A high score indicates better HRQoL,
with a high score on bodily pain representing absence of pain
Table 3 Recurrence rate of patients treated surgically or with
SBRT. Four patients had both loco-regional recurrence and
distant recurrence
Surgery (%) Radiotherapy (%)
All recurrence 9 (16) 3 (10)
Time till all
recurrence(mean ± SD)
1.1 ± 0.7 months 0.4 ± 0.06 months
Local recurrence 1 (2) –
Loco-regional recurrence 4 (7) 1 (3)
Distant recurrence 9 (16) 2 (7)
Death 5 (9) 8 (28)
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Although decisional conflict is about what patients go
through when confronted with a difficult decision, the
idea of decisional conflict is also to help patients to think
about participation in decision-making and motivate
them to engage in treatment decision-making [57]. Fur-
thermore, these scales also illustrate how patients are in-
formed and where the improvements are needed.
Health related quality of life and shared decision making
In general, lung cancer patients have poor HRQoL com-
pared to the general population or patients without lung
cancer [58, 59]. In this study, patients in the SBRT group
scored at baseline lower on physical component sum-
mary compared to patients treated surgically. No differ-
ences could be found regarding the mental component
summary. An explanation for the observed differences in
HRQoL between the two groups could be the significant
differences in baseline characteristics [2, 56]. No associ-
ation could be found between HRQoL and different as-
pect of SDM meaning that in this study HRQoL was not
positively or negatively influenced by patient experiences
with SDM. Our findings are comparable with a number
of studies concluding that there is weak evidence that
aspects of SDM are positively or negatively associated
with QoL outcomes [60].
Strengths and limitations
The present study is a prospective observational cohort
study allowing for new insights into the process of SDM
and information conveyance in lung cancer patients. Al-
though many articles have been written on SDM and pa-
tient participation in treatment decision-making in
cancer patients, to our knowledge little research has
been done on the role of early-stage lung cancer patients
-treated surgically or with SBRT- in treatment decision-
making and patients experiences and preferences regard-
ing SDM. Also, the lung cancer patients were surveyed
after diagnosis but before the treatment which allow us
to investigate the unbiased perception of the patient re-
garding the treatment decision-making.
Potential limitations need to be addressed regarding
the present study. First, the conceptual design of this
study was not built on a specific theory. We explicitly
chose to include all patients with stage I or II NSCLC
who were planned for a surgical treatment or SBRT. We
wanted to illustrate the patient participation in treat-
ment decision-making, since there is little research
about the role of early-stage lung cancer patients
-treated surgically or with SBRT- in treatment decision-
making. Second, overall response rate was 54% thus
making the sample size of this study small. The non-
responders were contacted to ask why they would not be
part of the study. The following major reasons were
given: 1) they were shocked by the diagnosis and
therefore they did not want to complete the question-
naire; 2) they were too preoccupied with their illness
and therefore they had no time for the questionnaire; 3)
the questionnaire was too confrontational. However, no
significant differences were found between responders
and non-responders in terms of baseline characteristics.
Third, we are aware of the shortcomings of using GLM.
By using the bootstrap method we have tried to account
for this inadequacy. However, no differences were ob-
served between the results of GLM and results of GLM
with bootstrapping. Finally, the response rate at 6 and
12 months was low due to recurrences rates and death
rates in both treatment groups making analyses of
HRQoL at 6 and 12 months difficult.
Conclusions
Shared-decision-making (SDM), where patients are in-
volved as active partners with the physician in treat-
ment decisions, is an important part of patient-
centered cancer care as it weighs the pros and cons
of treatment options while taking patients values and
preferences into account.
Dutch early-stage NSCLC patients find it important to
be involved in treatment decision-making. The majority
of patients in this study found it important to be in-
volved in decision-making and reported that they felt
sufficiently involved by their treating physician. Yet a
substantial proportion of patients experiences decisional
conflict and feels uninformed. HRQoL was not influ-
enced by patient experiences with SDM. Better patient
information, and patient involvement in treatment
decision-making is needed in order to improve patient
knowledge and hopefully reduce decisional conflict.
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